Dexmedetomidine use, Medetomidine

In areas with high medetomidine penetrance, clinicians reported a novel withdrawal syndrome among people with opioid use disorder, characterized by severe tachycardia, hypertension, vomiting, agitated delirium and tremor, with limited response to opioids but improvement with α2 agonists over 3-5 days. University of Pennsylvania reported trends in dexmedetomidine receipt and ICU admissions.